Company Profile
A clinical-stage biotech developing drugs that target the endocannabinoid system to treat serious inflammatory and fibrotic diseases including systemic sclerosis, lupus, and NASH.
Rank #20
CRBP
$8.89
-1.33% (24h)
Last updated: 1 second ago
Market Cap
$164.71M
Volume (24h)
209.55K
Last Close (7D)
$8.89
A clinical-stage biotech developing drugs that target the endocannabinoid system to treat serious inflammatory and fibrotic diseases including systemic sclerosis, lupus, and NASH.
52-Week Range